Study links Ozempic use to fewer psychiatric hospital stays in bipolar patients

A Griffith University study examined health data from 15,000 individuals across a 15-year span and discovered that people with bipolar disorder who were prescribed semaglutide, sold as Ozempic or Wegovy, faced a 21% reduction in psychiatric hospitalizations. Lead author Mark Taylor described the drop as "significantly lower rates." The protective effect appeared only for semaglutide; comparable GLP-1 medications like liraglutide (Victoza/Saxenda) and dulaglutide (Trulicity) did not show the same outcome.

The research proposes that GLP-1 receptor activation may curb brain inflammation and oxidative stress, mechanisms tied to mood instability. Prior studies have hinted at antidepressant-like effects of GLP-1 drugs and reduced suicidal thoughts in obese teens using semaglutide. Clinicians such as Lenard Adler have noted anecdotal improvements in attention and impulsivity among patients on these agents, though direct causality remains unproven.